Researchers at the University of Arizona have invented the first highly selective Nox4 small molecule inhibitors for the treatment of fibrotic disorders. Through Tech Launch Arizona, the office of the university that commercializes inventions stemming from research, the UA has licensed the technology to startup Fibronox to bring the invention from the lab to the...